MD HB1375

Requires health insurers, nonprofit health service plans, and HMOs in Maryland to cover the full length of long-term antibiotic treatment (defined as longer than 4 weeks) for Lyme disease and related tick-borne illnesses when ordered by a licensed physician for therapeutic purposes.

Prohibits insurers from imposing quantitative limitations on long-term antibiotic treatment or denying coverage solely because the treatment may be categorized as unproven, experimental, or investigational.

Defines "Lyme disease" broadly to include clinical diagnoses that may not meet CDC surveillance criteria, as well as late-stage, persistent, or chronic infections with Borrelia burgdorferi.

Covers related tick-borne illnesses including bartonellosis, babesiosis, ehrlichiosis, anaplasmosis, and piroplasmosis.

Takes effect January 1, 2027, applying to all policies, contracts, and health benefit plans issued, delivered, or renewed on or after that date.